![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PGM5 |
Gene summary for PGM5 |
![]() |
Gene information | Species | Human | Gene symbol | PGM5 | Gene ID | 5239 |
Gene name | phosphoglucomutase 5 | |
Gene Alias | PGMRP | |
Cytomap | 9q21.11 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q15124 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5239 | PGM5 | S014 | Human | Liver | HCC | 6.80e-30 | 8.62e-01 | 0.2254 |
5239 | PGM5 | S015 | Human | Liver | HCC | 4.22e-24 | 1.07e+00 | 0.2375 |
5239 | PGM5 | S016 | Human | Liver | HCC | 2.01e-40 | 1.04e+00 | 0.2243 |
5239 | PGM5 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 4.32e-04 | 3.62e-01 | 0.1633 |
5239 | PGM5 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 1.05e-06 | 4.51e-01 | 0.1608 |
5239 | PGM5 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 1.10e-10 | 5.99e-01 | 0.1604 |
5239 | PGM5 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 1.01e-04 | 4.46e-01 | 0.1602 |
5239 | PGM5 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 8.80e-03 | 5.38e-01 | 0.1622 |
5239 | PGM5 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 5.22e-06 | 4.19e-01 | 0.1575 |
5239 | PGM5 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 1.25e-03 | 3.77e-01 | 0.1545 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease | ||
Prostate | ![]() | BPH: Benign Prostatic Hyperplasia |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000599621 | Liver | HCC | monosaccharide metabolic process | 167/7958 | 257/18723 | 2.31e-13 | 1.25e-11 | 167 |
GO:001931821 | Liver | HCC | hexose metabolic process | 155/7958 | 237/18723 | 7.63e-13 | 3.90e-11 | 155 |
GO:000600621 | Liver | HCC | glucose metabolic process | 128/7958 | 196/18723 | 8.60e-11 | 3.06e-09 | 128 |
GO:003103222 | Liver | HCC | actomyosin structure organization | 109/7958 | 196/18723 | 1.39e-04 | 1.13e-03 | 109 |
GO:003103216 | Prostate | Tumor | actomyosin structure organization | 63/3246 | 196/18723 | 2.94e-07 | 6.72e-06 | 63 |
GO:006053714 | Prostate | Tumor | muscle tissue development | 107/3246 | 403/18723 | 1.93e-06 | 3.34e-05 | 107 |
GO:001470613 | Prostate | Tumor | striated muscle tissue development | 98/3246 | 384/18723 | 2.96e-05 | 3.56e-04 | 98 |
GO:000600613 | Prostate | Tumor | glucose metabolic process | 55/3246 | 196/18723 | 1.22e-04 | 1.14e-03 | 55 |
GO:004269213 | Prostate | Tumor | muscle cell differentiation | 93/3246 | 384/18723 | 3.45e-04 | 2.73e-03 | 93 |
GO:005114614 | Prostate | Tumor | striated muscle cell differentiation | 69/3246 | 283/18723 | 1.56e-03 | 9.54e-03 | 69 |
GO:00193187 | Prostate | Tumor | hexose metabolic process | 59/3246 | 237/18723 | 1.96e-03 | 1.14e-02 | 59 |
GO:00059967 | Prostate | Tumor | monosaccharide metabolic process | 62/3246 | 257/18723 | 3.38e-03 | 1.75e-02 | 62 |
GO:00550011 | Prostate | Tumor | muscle cell development | 45/3246 | 184/18723 | 8.73e-03 | 3.78e-02 | 45 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PGM5 | SNV | Missense_Mutation | novel | c.1598N>T | p.His533Leu | p.H533L | Q15124 | protein_coding | tolerated(0.67) | benign(0.058) | TCGA-BA-A6DA-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PGM5 | SNV | Missense_Mutation | rs200812025 | c.1427C>T | p.Thr476Met | p.T476M | Q15124 | protein_coding | deleterious(0.03) | benign(0.336) | TCGA-BA-A6DD-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
PGM5 | SNV | Missense_Mutation | novel | c.1241N>C | p.Val414Ala | p.V414A | Q15124 | protein_coding | deleterious(0.03) | probably_damaging(0.991) | TCGA-CN-4723-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PGM5 | SNV | Missense_Mutation | novel | c.1228N>T | p.Arg410Trp | p.R410W | Q15124 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-CN-4727-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
PGM5 | SNV | Missense_Mutation | rs782212102 | c.621C>G | p.Ile207Met | p.I207M | Q15124 | protein_coding | deleterious(0.01) | probably_damaging(0.937) | TCGA-CQ-7071-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PGM5 | SNV | Missense_Mutation | rs201672908 | c.1325N>T | p.Thr442Met | p.T442M | Q15124 | protein_coding | deleterious(0.03) | benign(0.042) | TCGA-CR-7379-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PGM5 | SNV | Missense_Mutation | novel | c.1344G>T | p.Arg448Ser | p.R448S | Q15124 | protein_coding | tolerated(0.46) | benign(0.071) | TCGA-CV-6935-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PGM5 | SNV | Missense_Mutation | novel | c.993G>C | p.Met331Ile | p.M331I | Q15124 | protein_coding | tolerated(0.11) | benign(0.062) | TCGA-CV-7245-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PGM5 | SNV | Missense_Mutation | rs782741271 | c.677G>A | p.Arg226His | p.R226H | Q15124 | protein_coding | tolerated(0.6) | benign(0.199) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
PGM5 | SNV | Missense_Mutation | rs782436052 | c.985C>T | p.Arg329Cys | p.R329C | Q15124 | protein_coding | tolerated(0.12) | benign(0.005) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |